Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FOG-001 |
Synonyms | |
Therapy Description |
FOG-001 inhibits the interaction between beta-catenin (CTNNB1) and TCF, resulting in decreased Wnt pathway signaling and potentially leading to decreased tumor growth (J Clin Oncol 42, 2024 (suppl 16; TPS3175), NCI Drug Dictionary) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FOG-001 | FOG 001|FOG001 | CTNNB1 Inhibitor 27 | FOG-001 inhibits the interaction between beta-catenin (CTNNB1) and TCF, resulting in decreased Wnt pathway signaling and potentially leading to decreased tumor growth (J Clin Oncol 42, 2024 (suppl 16; TPS3175), NCI Drug Dictionary) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05919264 | Phase Ib/II | FOG-001 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |